drugset / Trial / NCT00699608

An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

NCT00699608

Phase 3 Completed 91 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.

Timeline

Start
2008-07
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg
Subject Zopiclone Small molecule 7.5 mg